The management overview highlights Gilead Sciences, Inc. as a biopharmaceutical company committed to advancing innovative medicines, which underscores the importance of mobilizing and deploying IT-based resources in combination with leveraging the value of other resources and capabilities. The company’s strategic ambitions include expanding internal and external innovation, strengthening portfolio strategy and decision-making, and increasing patient benefit and access, reflecting a focus on operational flexibility and resource allocation. The strategic priorities aim to deliver transformative therapies and enhance organizational capabilities, which are essential for responding to market dynamics and consumer demands. The financial performance in 2020, despite the global impact of the COVID-19 pandemic, demonstrates the solid underlying fundamentals of the business, driven by the HIV franchise and increased demand for Veklury, indicating the significance of IT capabilities in supporting business needs and enhancing operational efficiency. The company also emphasizes the need for strategic resource allocation to support research and development efforts, which are crucial for maintaining competitive advantage and achieving business transformation. The acquisition of Immunomedics and Forty Seven reflects Gilead’s commitment to expanding its technology portfolio and enhancing its capabilities in oncology, which is aligned with the evolving scope of IT capabilities that encompass coordination of firm assets and internal processes. The management discusses the importance of information management capability, emphasizing the ability to provide data and information to users with appropriate levels of accuracy, timeliness, reliability, security, confidentiality, connectivity, and access, which are critical for effective decision-making and operational efficiency. The company’s focus on strategic management practices and technology deployment is evident in its efforts to optimize processes and enhance firm performance through actionable investments and innovation partnerships. The discussion of financial activities highlights the impact of investment decisions on the company’s ability to adapt to changing market conditions and maintain operational agility. The emphasis on technology integration and the development of digital infrastructure supports the company’s goal of delivering life-changing medications and achieving performance excellence. The management’s discussion also reflects on the challenges posed by regulatory uncertainty and competitive actions, which necessitate a robust IT governance framework to ensure compliance and facilitate effective resource management. Overall, Gilead’s strategic direction and operational focus illustrate the critical role of IT capabilities in driving business innovation, enhancing organizational effectiveness, and achieving long-term growth objectives.